title: [Clinical aspects of primary myelofibrosis in Japan].
authors.forename: Kazuya
authors.initials: K
authors.lastname: Shimoda
authors.forename: Katsuto
authors.initials: K
authors.lastname: Takenaka
authors.forename: Akira
authors.initials: A
authors.lastname: Kitanaka
authors.forename: Koichi
authors.initials: K
authors.lastname: Akashi
mesh_terms: D001772:Blood Cell Count; D003613:Danazol / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007564:Japan; D008710:Methenolone / Q000031:analogs & derivatives / Q000627:therapeutic use; D010166:Palliative Care; D011239:Prednisolone / Q000627:therapeutic use; D055728:Primary Myelofibrosis / Q000097:blood / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D011379:Prognosis; D011878:Radiotherapy / Q000379:methods; D013154:Spleen; D015996:Survival Rate; D019172:Transplantation Conditioning
chemical_list: D008710:Methenolone; D011239:Prednisolone; D003613:Danazol; C033244:methenolone acetate; D006918:Hydroxyurea